Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in SDGR.
← Back to Free Index

SDGR

Analysis as of: 2026-06-21
Schrödinger, Inc.
Schrödinger sells computational molecular discovery software and workflow tools and also monetizes its platform through collaborations and selected internal drug programs.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A real workflow moat, still needing proof
The upside case is a cleaner, hosted discovery operating layer that monetizes more throughput as AI speeds molecular design. The stock can more than double by 2031, but only if product launches convert into sticky usage and not just scientific credibility.

Analysis

Thesis
Schrödinger can more than double equity value by 2031 if hosted delivery, LiveDesign workflow control, and Bunsen-driven throughput turn a respected science stack into a broader discovery operating layer, while partnerships keep therapeutics upside without forcing a capital-heavy biotech rebuild.
Last Economy Alignment
Cheaper cognition and compute expand demand for computational discovery, and Schrödinger has a real capture surface in workflow-embedded, usage-led software. The cap on alignment is that big pharma can still in-source tools or let generic agents bypass part of the interface.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.0x (from 5 most recent analyses)
Reasoning
This is a quality-of-revenue and control-point rerating story more than a moonshot pipeline story. If hosted contracts mature well, Bunsen expands paid workflow surface area, and partner economics stay asset-light, Schrödinger can exit the current transition as a cleaner discovery workflow company with better revenue durability and a larger monetization surface than the market now credits.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not survival but value capture. Schrödinger must prove that hosted ACV growth, Bunsen usage, and deeper workflow embedding become durable commercial economics before internal pharma stacks, generic AI tools, or execution slippage reduce the business to a lower-multiple scientific utility.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.51
They control a shared discovery workspace and a physics engine that can keep more AI-driven science inside a paid system as research speeds up. The risk is that big pharma may let cheaper internal or generic agents talk directly to its own tools, leaving Schrödinger useful but less central.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$20.88
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case